Patients included will undergo biopsy and the molecular analysis will be discussed at the
institutional molecular tumor board. The recommandation of the molecular tumor board will be
provided to the physician in charge of the patient for final treatment desicion.
The main endpoints are the number of patients with actionable molecular alterations, the
number of patients with a treatment recommendation, the number of patients receiving the
recommended therapy, overall survival of the patients treated according to recommendations or
not. For patients treated according to the recommendations: Response rate and progression
free survival at 6 months according to RECIST criteria.